Abstract:Aims: It is increasingly appreciated that coordinated regulation of angiogenesis and osteogenesis is needed for bone formation. How this regulation is achieved during peri-implant bone healing, such as osseointegration, is largely unclear. This study examined the relationship between angiogenesis and osteogenesis in a unique model of osseointegration of a mouse tibial implant by pharmacologically blocking the vascular endothelial growth factor (VEGF) pathway. Materials and methods: An implant was inserted into the right tibia of 16-week-old female C57BL/6 mice (n = 38). Mice received anti-VEGF receptor-1 (VEGFR-1) antibody (25 mg/kg) and VEGF receptor-2 (VEGFR-2) antibody (25 mg/kg; n = 19) or an isotype control antibody (n = 19). Flow cytometric (n = 4/group) and immunofluorescent (n = 3/group) analyses were performed at two weeks post-implantation to detect the distribution and density of CD31hiEMCNhi endothelium. RNA sequencing analysis was performed using sorted CD31hiEMCNhi endothelial cells (n = 2/group). Osteoblast lineage cells expressing osterix (OSX) and osteopontin (OPN) were also detected with immunofluorescence. Mechanical pull-out testing (n = 12/group) was used at four weeks post-implantation to determine the strength of the bone-implant interface. After pull-out testing, the tissue attached to the implant surface was harvested. Whole mount immunofluorescent staining of OSX and OPN was performed to determine the amount of osteoblast lineage cells. Results: Flow cytometry revealed that anti-VEGFR treatment decreased CD31hiEMCNhi vascular endothelium in the peri-implant bone versus controls at two weeks post-implantation. This was confirmed by the decrease of CD31 and endomucin (EMCN) double-positive cells detected with immunofluorescence. In addition, treated mice had more OPN-positive cells in both peri-implant bone and tissue on the implant surface at two weeks and four weeks, respectively. More OSX-positive cells were present in peri-implant bone at two weeks. More importantly, anti-VEGFR treatment decreased the maximum load of pull-out testing compared with the control. Conclusion: VEGF pathway controls the coupling of angiogenesis and osteogenesis in orthopaedic implant osseointegration by affecting the formation of CD31hiEMCNhi endothelium. Cite this article: Bone Joint J 2019;101-B(7 Supple C):108-114.

Expression of vascular endothelial growth factor in bone morphogenetic protein-2 induced osteogenesis

[Expression of Human VEGF165 Gene in Rat Bone Marrow Stromal Cells in Vitro].

Osteogenic Role of Vascular Endothelial Growth Factor in Bone Regeneration.

[Assessment of the Expression Profile During the Entochondrostosis of Vascular Endothelial Growth Factor in Bone Morphogenetic Protein 2 Induced Osteogenesis].

In vivo ectopic osteogenesis of mouse bone marrow stromal stem cells transfected with bone morphogenetic protein 2 and vascular endothelial growth factor 165 genes

Ectopic Osteogenesis of Mouse Bone Marrow Stromal Cells Transfected with BMP 2/VEGF165 Genes in Vivo

Vascular endothelial growth factor promotes the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells

Relationship Between Ad-BMP-2 and VEGF and Their Role in the Ossification

Effects of BMP-2 and FGF2 on the Osteogenesis of Bone Marrow-Derived Mesenchymal Stem Cells in Hindlimb-Unloaded Rats

EXPRESSION OF NERVE GROWTH FACTOR AND ITS RECEPTOR DURING OSTEOINDUCTION OF RECOMBINED HUMAN BONE MORPHOGENETIC PROTEIN 2

Osteogenic potentiality of deproteinized bone composited with dog marrow stromal cells transfected with VEGF165 gene after implantation into nude mice

Role of vascular endothelial growth factor in osteogenesis induced by bone morphogenetic protein-2

Adenovirus-mediated expression of vascular endothelial growth factor-a potentiates bone morphogenetic protein9-induced osteogenic differentiation and bone formation

Ectopic Bone Formation Using Bone Morphogenetic Protein 2 Adenoviral Vector

Synergistic Effects of Controlled-Released BMP-2 and VEGF from nHAC/PLGAs Scaffold on Osteogenesis

Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification

Vascular endothelial growth factor pathway promotes osseointegration and CD31hiEMCNhi endothelium expansion in a mouse tibial implant model: an animal study

VEGF and BMP-2 Promote Bone Regeneration by Facilitating Bone Marrow Stem Cell Homing and Differentiation

Bone Marrow Stromal Cells with A Combined Expression of Bmp-2 and Vegf-165 Enhanced Bone Regeneration

The expression of bone formation-correlative factors in allograft bone implantation

Effects of Different Ratios of BMP2 and VEGFA on the Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells